Neoadjuvante Therapie mit 177Lu-DOTATATE bei nichtfunktionellen neuroendokrinen Tumoren des Pankreas (NEOLUPANET): eine multizentrische Phase-II-StudieNeoadjuvant treatment with 177Lu-DOTATATE for nonfunctional neuroendocrine tumors of the pancreas (NEOLUPANET): a multicenter phase II study

被引：0
|
作者：
Ioannis Mintziras [1 ]
Detlef K. Bartsch [1 ]
机构：
[1] Philipps-Universität Marburg,Klinik für Visceral‑, Thorax
来源：
Die Chirurgie | 2025年 / 96卷 / 1期
关键词：
D O I：
10.1007/s00104-024-02205-8
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：63 / 64
页数：1
相关论文
共 28 条
  • [21] 177Lu-DOTATATE plus 166Ho-radioembolization in patients with neuroendocrine tumours: A single center, prospective, interventional, non-comparative, open label, phase II study (HEPAR PLUS study)
    Braat, A. J. A. T.
    van Rooij, R.
    Bruijnen, R. C. G.
    Braat, M. N. G. J. A.
    Wessels, F.
    van Leeuwaarde, R. S.
    van Treijen, M.
    de Jong, H. W. A. M.
    Lam, M. G. E. H.
    ANNALS OF ONCOLOGY, 2019, 30
  • [22] 177Lu-DOTATATE Plus 166Ho-Radioembolization in Patients with Neuroendocrine Tumours; A Single Center, Prospective, Interventional, Non-Comparative, Open Label, Phase II Study (HEPAR PLuS Study)
    Braat, A.
    Rutger, B.
    Van Rooij, R.
    Braat, M.
    Wessels, F.
    van Leeuwaarde, R.
    van Treijen, M.
    de Herder, W. W.
    Hofland, J.
    Tesselaar, M.
    de Jong, H.
    Lam, M.
    NEUROENDOCRINOLOGY, 2020, 110 : 249 - 249
  • [23] Randomized, parallel arm, phase II study of telotristat (Xermelo) in combination with lutetium Lu 177 dotatate (Lutathera) in well-differentiated neuroendocrine tumors (NETs)
    Chauhan, Aman
    Kunos, Charles
    Yan, Donglin
    Khurana, Aman
    Khouli, Riham
    Cavnar, Michael J.
    Pandalai, Prakash
    Kim, Joseph
    Anthony, Lowell Brian
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [24] Outcome prediction in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT): results from a prospective phase II clinical trial
    Mileva, M.
    Marin, G.
    Levillain, H.
    Artigas, C.
    Van Bogaert, C.
    Marin, C.
    Danieli, R.
    Deleporte, A.
    Jungels, C.
    Vanderlinden, B.
    Wimana, Z.
    Hendlisz, A.
    Flamen, P.
    Karfis, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S106 - S106
  • [25] Safety and organs-at-risk dosimetry in patients with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) treated with 177Lu-DOTATATE peptide receptor radionuclide therapy (PRRT): data from prospective phase II clinical trial
    Mileva, M.
    Van Bogaert, C.
    Marin, G.
    Levillain, H.
    Artigas, C.
    Marin, C.
    Danieli, R.
    Deleporte, A.
    Jungels, C.
    Vanderlinden, B.
    Wimana, Z.
    Hendlisz, A.
    Flamen, P.
    Karfis, I.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S103 - S103
  • [26] Phase 1 Study of No-Carrier Added 177Lu-DOTATATE (SNU-KB-01) in Patients with Somatostatin Receptor-Positive Neuroendocrine Tumors: The First Clinical Trial of Peptide Receptor Radionuclide Therapy in Korea
    Ryoo, Hyun Gee
    Suh, Minseok
    Kang, Keon Wook
    Lee, Dae-Won
    Han, Sae-Won
    Cheon, Gi Jeong
    CANCER RESEARCH AND TREATMENT, 2023, 55 (01): : 334 - 343
  • [27] Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)
    Braat, Arthur J. A. T.
    Kwekkeboom, Dik J.
    Kam, Boen L. R.
    Teunissen, Jaap J. M.
    de Herder, Wouter W.
    Dreijerink, Koen M. A.
    van Rooij, Rob
    Krijger, Gerard C.
    de Jong, Hugo W. A. M.
    van den Bosch, Maurice A. A. J.
    Lam, Marnix G. E. H.
    BMC GASTROENTEROLOGY, 2018, 18
  • [28] Additional hepatic 166Ho-radioembolization in patients with neuroendocrine tumours treated with 177Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)
    Arthur J. A. T. Braat
    Dik J. Kwekkeboom
    Boen L. R. Kam
    Jaap J. M. Teunissen
    Wouter W. de Herder
    Koen M. A. Dreijerink
    Rob van Rooij
    Gerard C. Krijger
    Hugo W. A. M. de Jong
    Maurice A. A. J. van den Bosch
    Marnix G. E. H. Lam
    BMC Gastroenterology, 18
123